Key issues in F₂-isoprostane analysis

Jaffar Nourooz-Zadeh¹
Department of Clinical and Nutritional Biochemistry, Urmia University of Medical Sciences, P.O. Box 1138, Urmia 57135, Iran

Abstract

A large body of evidence indicates that measurement of F₂-isoprostanes, specific prostaglandin F₂-like compounds derived from the non-enzymatic peroxidation of arachidonic acid, is a reliable biomarker of oxidant stress in the human body. Since the discovery of F₂-isoprostanes in the early 1990s, a variety of analytical approaches has been introduced for the quantification of these novel compounds. The aim of the present review is to shed light on the available gas chromatographic–mass spectrometric assays for the measurement of plasma or urinary F₂-isoprostanes and to highlight a number of issues which need to be addressed in order to implement F₂-isoprostane measurement as a gold-standard biomarker of oxidative stress in biological samples.

Introduction

The term oxidative stress was first employed as the title of a book edited by Sies [1]. In the introduction to the second edition of this book, oxidative stress was defined as a disturbance in the pro-oxidant/antioxidant balance in favour of the former, which may lead to tissue damage [2]. Halliwell has defined oxidative stress as a serious imbalance between production of ROS (reactive oxygen species)/RNS (reactive nitrogen species)/RCS (reactive chlorine species) and antioxidant defences [3]. Baynes and Thorpe [4], on the other hand, have introduced a definition comprising both quantitative aspects of oxidative stress and chemical modification of target molecules. Oxidative stress was defined as a measure of the prevailing levels of ROS in biological systems [4]. They also emphasized that this definition takes account of the continuous detection of ROS in biological systems determined by the relative rates of their formation and removal by cellular repair mechanisms [4].

An array of analytical tools is available for lipid peroxidation products, including TBARSs (thiobarbituric acid-reactive substances), lipid hydroperoxides, hydroxylated fatty acids, volatile hydrocarbons, aldehydes and cholesterol auto-oxidation products, protein carbonyls, aldehyde-modified proteins, oxidatively damaged DNA and total antioxidant capacity for the precise measurement of oxidative stress in vivo [5–7]. However, problems arise when the above-mentioned methods are applied to in vivo samples.

A major step forward regarding the measurement of lipid peroxidation products came with the discovery of F₂-isoprostanes [8,9]. The F₂-isoprostanes are a family of PG (prostaglandin)-like compounds produced by non-enzymatic peroxidation of arachidonic acid. The formation of F₂-isoprostanes from arachidonic acid involves allylic hydrogen abstraction, formation of an arachidonoyl radical, insertion of molecular oxygen and endocyclization to form a bicyclic endoperoxide followed by insertion of a second oxygen molecule.

Four possible subfamilies of F₂-isoprostanes are formed as a result of radical attack at C7, C10 and C13 (Figure 1). Series 5 (Type VI) F₂-isoprostanes are derived from free radical attack at C7. Series 8 (Type V) and series 12 (Type IV) result from free radical attack at C10. Series 15 (Type III) is derived from free radical attack at C13. Each subfamily comprises 16 diastereoisomers, since the hydroxy group on the cyclopentane ring can be arranged in eight different configurations. In total, 64 F₂-isoprostane isomers can be formed during peroxidation of arachidonic acid [7,10]. Of these, 8-epi-PGF₂α (also known as 8-iso-PGF₂α or 15-F₂t-isoprostane) has received most attention because it has been shown to possess certain adverse biological activities [11–14]. Circulating 8-epi-PGF₂α is mainly present bound to phospholipids in situ and is released by the action of phospholipase A₂ [15]. Figure 1 shows proposed pathways for the generation of the different F₂-isoprostane families during non-enzymatic peroxidation of arachidonic acid.

Historic background

We owe our knowledge of isoprostanes to Nugteren [16] for his pioneering investigations into the metabolism of prostaglandins. Nugteren was interested in developing a less cumbersome procedure for the determination of the excretion rate of prostaglandins and their metabolites in humans using a strategy that would limit the number of detected compounds in the final lipid extract, exhibit higher recovery and allow preparation of stable derivatives before final determination by GC–MS [16]. His approach involved hydrogenation to eliminate double bonds and removal of hydroxy and keto moieties from the molecule while leaving the prostanoïd backbone intact. In healthy volunteers, excretion of unmetabolized PGF₂α was estimated to be approx. 300 μg/day. This
Figure 1 | Proposed pathways for the formation of the different F₂-isoprostane families during auto-oxidation of arachidonic acid

Figure 2 | Proposed pathways for biosynthesis and metabolism of prostaglandins

quantity was substantially higher than the sum of PGF₂α (males, 24.0 ± 17.2 μg/day; females, 10.5 ± 2.1 μg/day) and PGE₂ (males 15.5 ± 13.6 μg/day; females, 4.1 ± 0.8 μg/day) reported previously by other investigators [17,18]. It was also reported that excretion of various tetranorprostaneacid derivatives was 0.2 ± 0.08 mg/mg of creatinine. In addition, it was found that only 15–30% of intravenously administrated PGF₂α was excreted as tetranorprostaneacid derivatives. Therefore it was proposed that prostanoids (partially or fully degraded) other than tetranorprostaneacid derivatives should be present in human urine. Figure 2 shows the pathways proposed by Nugteren [16] for the biosynthesis and metabolism of prostaglandins in humans.

In 1988, Wendelborn et al. [19] reported that healthy subjects exhibited 48–460 pg/ml of urinary PGF₂-like compounds. The corresponding levels for circulating PGF₂-like compounds was in the range 1–12 pg/ml. Interestingly, they found that the mean concentration of PGF₂-like compounds increased 800-fold in patients with systemic mastocytosis. The initial explanation for the presence of markedly elevated levels of PGF₂-like compounds in patients with systemic mastocytosis was isomerization of PGD₂ to PGF₂ involving reduction of the keto moiety (C11) on PGD₂ and thus yielding more stable PGF₂-like compounds.

In order to elucidate whether PGF₂-like compounds were derived from the rearrangement of endogenous PGD₂, the configuration of the hydroxy groups on the cyclopentane ring was determined. Total lipid extracts from plasma and urine from the above-mentioned samples were therefore treated with n-butylboronic acid. n-Butylboronic acid forms
Table 1 | Events that led to the emergence of F2-isoprostanes as a novel biomarker of oxidative stress

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td>The determination of prostaglandin metabolites in human urine [16]</td>
</tr>
<tr>
<td>1988</td>
<td>Discovery of PGF2 isomers derived from PGD2 metabolism in human plasma and urine [19]</td>
</tr>
<tr>
<td>1990</td>
<td>Proposed mechanism for the free-radical-catalysed formation of a series of novel prostaglandins in vivo [8]</td>
</tr>
<tr>
<td>1991</td>
<td>Quantification of F2-isoprostanes as a marker of oxidative stress [9]</td>
</tr>
<tr>
<td>1992</td>
<td>Formation of F2-isoprostanes in CCl4-induced hepatotoxicity [45]</td>
</tr>
<tr>
<td>1993</td>
<td>Evidence for in situ formation of F2-isoprostanes in phospholipids [12]</td>
</tr>
<tr>
<td>1991</td>
<td>Evidence for the existence of F2-isoprostane receptors on vascular smooth muscle cells [46]</td>
</tr>
<tr>
<td>1994</td>
<td>Measurement of a marked increase of F2-isoprostanes in the hepatorenal syndrome [47]</td>
</tr>
<tr>
<td>1995</td>
<td>Identification of F2-isoprostane metabolites in human urine [48]</td>
</tr>
<tr>
<td>1994</td>
<td>Measurement of the formation of F2-isoprostanes during exposure of LDL to peroxynitrite [49]</td>
</tr>
<tr>
<td>1995</td>
<td>Detection of esterified F2-isoprostanes in native LDL [50,51]</td>
</tr>
<tr>
<td>1993</td>
<td>Detection of increased levels of F2-isoprostanes in smokers [52]</td>
</tr>
<tr>
<td>1994</td>
<td>A new GC–MS assay for the analysis of F2-isoprostanes [23]</td>
</tr>
<tr>
<td>1995</td>
<td>Measurement of an enhanced level of 8-epi-PGF2α in Type 2 diabetic subjects [53]</td>
</tr>
<tr>
<td>1996</td>
<td>Immunological characterization of urinary 8-epi-PGF2α [54]</td>
</tr>
<tr>
<td>1993</td>
<td>Evidence for the generation of 8-epi-PGF2α by human platelets [55]</td>
</tr>
</tbody>
</table>

a cyclic derivative when reacting with cis-1,3-dihydroxy moieties on a cyclopentane ring. GC–MS analysis revealed that approx. 67% of the 16 detected PGF2-like compounds contained cis-oriented hydroxy groups, thus suggesting that a predominant number of PGF2-like compounds present in plasma or urine was not derived from the reduction of PGD2. Although several possible mechanisms were suggested to explain the presence of PGF2-like compounds (i.e. having cis-oriented cyclopentane hydroxy groups), none seemed to be entirely satisfactory.

In 1990, Roberts and co-workers reported the discovery of a new series of PGF2-like compounds (F2-isoprostanes) formed independently of PGD2 isomerization and the cyclo-oxygenase pathway [8,9]. They proposed that F2-isoprostanes were generated following an increase in free-radical-mediated oxidation of arachidonic acid. The events that led to the emergence of F2-isoprostanes as a novel biomarker of oxidative stress are summarized in Table 1.

**Quantification of F2-isoprostanes**

There are several approaches to the enrichment and final determination of F2-isoprostanes in biological samples. These include chromatographic separation involving SPE (solid-phase extraction) or affinity chromatography with or without TLC followed by final determination by GC–MS, LC (liquid chromatography)–MS, RIA or EIA (enzyme immunoassay). GC–MS/NICI (negative-ion chemical ionization) employing stable isotope dilution is the preferred method for the quantification of F2-isoprostanes, combining the high resolution of GC separation on fused silica capillary columns with the specificity and sensitivity of MS [20].

**Assessment of plasma F2-isoprostanes**

Mainstream analytical approaches for the enrichment of plasma 8-epi-PGF2α before final determination by GC–MS/NICI include: (i) chromatography on a C18 cartridge followed by TLC [21]; (ii) two chromatography steps (i.e. C18 and silica cartridges) followed by HPLC [22]; and (iii) chromatography steps combining C18 and NH2 cartridges [23]. Advantages of the procedure combining C18 and NH2 cartridges are that it is less labour-intensive than the other method involving TLC and is acceptable with respect to efficiency of extraction (~75%). It is noteworthy that the original enrichment procedure developed by Nourooz-Zadeh et al. [23] has recently been simplified in order to increase sample output (Figure 3). The modifications involved the use of a single extraction step of total lipids with ethyl acetate and the simplification of the NH2-chromatographic step by omitting two cartridge washes [24]. Figure 3 compares values for plasma total (sum of free and esterified) 8-epi-PGF2α using the modified enrichment by Nourooz-Zadeh [24] with those obtained by other investigators [22,25–28]. A slightly different approach has been undertaken by Schwedhelm et al. [29] for the quantification of F2-isoprostanes by GC–MS/NICI. The enrichment procedure involves combining chromatography on a C18 cartridge with TLC before the final determination by GC–MS/MS (tandem MS).
Assessment of urinary \( F_2 \)-isoprostanes

A number of disadvantages, however, are associated with the measurement of plasma 8-epi-PGF\(_{2\alpha}\) because it is cleared rapidly from the circulation (within approx. 16 min). This means that its quantification in the circulation will only provide information regarding a discrete point in time [8]. As a result, if large changes occur in the production of lipid peroxides over a particular period, the levels of 8-epi-PGF\(_{2\alpha}\) measured in a single sample of blood will not provide an accurate integrated assessment of oxidative stress. Secondly, artefactual generation of 8-epi-PGF\(_{2\alpha}\) can occur with improper sample handling and/or prolonged storage, leading to spurious results. The quantification of urinary 8-epi-PGF\(_{2\alpha}\) has therefore been proposed as being superior to the measurement of circulating 8-epi-PGF\(_{2\alpha}\) levels, as it is believed to represent a more accurate systemic index of oxidative stress. Various analytical approaches are available for the enrichment of urinary \( F_2 \)-isoprostanes before final determination by GC–MS/NICI. These include: (i) conventional procedures involving chromatography on C\(_{18}\) and silica cartridges followed by TLC [21]; (ii) a combination of C\(_{18}\) and silica cartridges followed by HPLC [22]; (iii) the inclusion of an HPLC step between C\(_{18}\)-chromatography and TLC [30]; and (iv) immunoaffinity chromatography [31]. It is worth noting that the FitzGerald group has employed chromatography on C\(_{18}\) cartridges followed by two steps of TLC for the enrichment of urinary \( F_2 \)-isoprostanes (Type I) before final quantification by GC–MS/NICI [32].

Nourooz-Zadeh et al. [33,34] have adopted another approach for the rapid enrichment of urinary \( F_2 \)-isoprostanes before final determination by GC–MS/NICI. The assay involved total lipid extraction and chromatographic sample enrichment on NH\(_2\) and silica cartridges before final determination by GC–MS/NICI. Inter- and intra-assay coefficients of variation for urinary 8-epi-PGF\(_{2\alpha}\) were acceptable at 5 and 7% respectively. Schematic outlines of the improved analytical procedures for the enrichment of plasma or urinary \( F_2 \)-isoprostanes are shown in Figure 4. Using the combined ethyl acetate extraction/NH\(_2\)/silica cartridges procedure, it was found that absolute 8-epi-PGF\(_{2\alpha}\) excretion in healthy subjects \((n=12)\) was 2.02±0.39 nmol/l. The respective value for 8-epi-PGF\(_{2\alpha}\) concentration relative to that of creatinine excretion was 31.8±15.9 pmol/mmol. As seen in Figure 5, the values obtained by us were in the same range as those reported previously by other investigators employing fairly similar GC–MS/NICI-based assays [29,35]. Also, the values for absolute...
urinary 8-epi-PGF2α concentrations, employing the combined total lipid/C18/NH2 procedure, were also comparable with those reported previously for male and female control subjects (1.49±0.36 and 2.05±0.87 nmol/l respectively) [30].

In addition to mainstream techniques in the field, a variety of other mass spectrometric (i.e. GC or LC) assays have been devised for the measurement of F2-isoprostanes or simultaneous determination of F2-isoprostanes and other lipid peroxidation products [36–44]. Further studies are, however, needed to evaluate the reliability and specificity of these methods and their usefulness for clinical trials.

In conclusion, a large body of evidence suggests that measurement of F2-isoprostanes is a reliable biomarker of oxidative stress in the human body. However, there are several key issues which need to addressed: (i) different conventions with regard to the nomenclature of isoprostanes are used by leading laboratories in the field; (ii) many types of GC–MS or LC–MS assays with variable quality have also been developed for the assessment of F2-isoprostanes, but firm data are still missing with regard to the specificity, accuracy and validity of the assays; (iii) no standard protocol is available for handling and/or storage of biological samples; and (iv) confusion exists concerning the metabolic fate of isoprostanes as a gold-standard biomarker of oxidative stress.

References
